Boceprevir
RxNorm 1102129
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1102129 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: boceprevir.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
IN
Ingredient (IN):
Boceprevir
(Atom ID: 4217034)
PT
Designated preferred name (PT):
Boceprevir
(Atom ID: 5939369)
FN
Full form of descriptor (FN):
Boceprevir (substance)
(Atom ID: 5939370)
PT
Designated preferred name (PT):
Boceprevir-containing product
(Atom ID: 10798236)
FN
Full form of descriptor (FN):
Product containing boceprevir (medicinal product)
(Atom ID: 9254405)
Patient Education
Boceprevir
Boceprevir is used along with two other medications (ribavirin [Copegus, Rebetol] and peginterferon alfa [Pegasys]) to treat chronic hepatitis C (an ongoing viral infection that damages the liver) in people who have not yet been treated for this condition or whose condition did not improve when they were treated with ribavirin and peginterferon alfa alone. Boceprevir is in a class of medications called protease inhibitors. It works by decreasing the amount of hepatitis C virus (HCV) in the body. Boceprevir may not prevent the spread of hepatitis C to other people.
[Learn More]
* Please review the disclaimer below.